Navigation Links
CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL ("good" cholesterol) levels, may reduce the amount of plaque in the coronary arteries of patients with a recent episode of acute coronary syndrome (ACS).

ACS is the term used to describe unstable angina and myocardial infarction (heart attack). It is estimated to be responsible for up to 600,000 admissions to the hospital per year in the US. Despite improvements in management over many years, ten to fifteen percent of patients still experience a serious cardiovascular problem in the 12 months following an episode of ACS.

CSL-111 is a patented biologic product, consisting of apolipoprotein A-I purified from human plasma that is reconstituted to form a particle that chemically and biologically resembles human HDL. A 40 mg/kg dose of CSL-111 results in an approximately 50 percent elevation in blood HDL levels, which remain above normal for one week. It was discovered and is manufactured at CSL Behring in Switzerland.

The Effect of Reconstituted HDL on Atherosclerosis - Safety and Efficacy (ERASE) trial was a phase 2, randomized, blinded, placebo-controlled study conducted at 17 sites throughout Canada and coordinated by the Montreal Heart Institute. The trial examined whether four infusions of CSL-111, given at weekly intervals to patients with a recent episode of ACS, could reduce the volume of plaque in the coronary arteries. Assessment of the arteries was performed using intravascular ultrasound (IVUS) and quantitative coronary angiography (QCA) before and two-three weeks after the treatment. IVUS is a technique in which a tiny ultrasound probe is inserted into the coronary arteries to determine the change in plaque during treatment. Coronary angiography is an X-ray
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:7/2/2015)... NYACK, N.Y. , July 2, 2015  Before you ... plan ahead so you can stay safe and healthy. Take ... plants #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your ... rays from the sun can increase your risk of skin ... the shade as much as possible, especially during midday hours. ...
(Date:7/2/2015)... According to a new market research ... Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, ... published by MarketsandMarkets, the global Neuromodulation Market is estimated at ... Billion by 2020, at a CAGR of 11.2% during the ... 4 market data T ables and ...
(Date:7/2/2015)... --  EVO Aesthetic Center and Wellness Spa prides ... in Lakeway, Texas and will ... Duality laser. The medical spa is focused on helping ... laser procedures. Their addition of the Astanza Duality will ... their tattoo regret. "The large number of ...
Breaking Medicine Technology:First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
...  Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the ... two pivotal studies in the Company,s OBI-1 Accur8 ... study, OBI-1, an intravenous recombinant porcine factor VIII ... of individuals with congenital hemophilia A who have ...
...   Acuo Technologies®, the leader in high-performance ... management and data migration, announced today that CHRISTUS ... as the company,s new vendor neutral archive solution. ... providing an enterprise foundation for future on-premise and ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1 2Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1 3Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1 4Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1 5Acuo Technologies Announces Vendor Neutral Archiving Contract with CHRISTUS Health 2
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national chief nursing officer ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are great for documenting memories. , Almost every smartphone has an incredibly powerful camera ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Report,with the Securities and Exchange Commission. Consolidated gross ... 2008 were $6,121,632 compared,to $5,713,761 for the same ... strong growth of the over-the-counter (OTC) product line ...
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... ,magic bullet, to help miilions of children in ... News) -- A new compound that may lead to ... by researchers at the University of Texas Health Science ... especially important for developing countries, where diarrhea is a ...
... a doctor could get a lot longer if the current ... increase soon, according to a new University of Missouri study. ... the MU School of Medicine, and his research team found ... 44,000 family physicians and general internists in less than 20 ...
... blood tests for breast, ovarian cancers, HERNDON, ... (CIT), a state-chartered non-profit, announced today,that its GAP ... of Funds, made,a $100,000 early-stage investment in OTraces, ... accurate and sensitive blood screening,tests for breast and ...
... in less than 90 seconds ... Varian Medical Systems, DECATUR, Ill., June 17 Decatur ... third in the,United States, to treat a cancer patient using ... John Hosler, an,85-year-old prostate cancer patient, received his treatment in ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 2Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 4Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 5Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:CIT GAP Funds Invests in OTraces, Inc. 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 3
... start with small things. The extremely ... of the trailblazers of the new,generation ... towards ever smaller access and the ... site. ,The HiLAN XS motor concept ...
The CRW system is the premier stereotactic system. The CRW system can be configured as a basic CT-only system, a CT/MR scanner-dependent system, or a high-level CT/MR scanner-independent system with ...
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility....
... are unique corticocancellous allografts comprised of ... unique Dovetail geometry permitting a precise ... Allografts are processed from donor vertebral ... Specially designed instruments facilitate the insertion ...
Medicine Products: